Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model

Sabrina Stücker1,2, Nico Kresin1,2, Lucie Carrier1,2

  • 1Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-EppendorfHamburg, Germany.

Frontiers in Physiology
|August 22, 2017
PubMed

Insights

Nebivolol desensitized cardiac muscle to calcium in a mouse model of hypertrophic cardiomyopathy (HCM). However, nebivolol did not affect calcium sensitivity in human HCM cardiac muscle.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by diastolic dysfunction and preserved systolic function.
  • Current therapies target hypercontractility via beta-blockers and calcium channel blockers.
  • Increased myofilament calcium sensitivity is a key mechanism in HCM's hypercontractile phenotype.

Purpose of the Study:

  • To evaluate nebivolol's effect on cardiac muscle strips from a Mybpc3-targeted knock-in (KI) HCM mouse model.
  • To investigate nebivolol and epigallocatechin-gallate's actions on human HCM cardiac strips with MYBPC3 mutations.

Main Methods:

  • Skinned ventricular muscle strips from Mybpc3 KI and wild-type (WT) mice were used.
  • Contractile parameters and force-calcium relationships were assessed.
  • Human cardiac strips from three MYBPC3-mutated HCM patients were analyzed.

Main Results:

  • Nebivolol induced myofilament calcium desensitization in both WT and KI mouse cardiac strips.
  • This calcium desensitization was more pronounced in KI mouse strips.
  • Nebivolol showed no effect on calcium sensitivity in human HCM cardiac muscle strips.

Conclusions:

  • Nebivolol demonstrates potential for myofilament calcium desensitization in an HCM mouse model.
  • The drug's efficacy differs between mouse models and human HCM cardiac tissue.
  • Further research is needed to understand nebivolol's therapeutic potential in human HCM.